Last reviewed · How we verify

NCT03887338

Systematic Laryngoscopic Evaluation of Upper Airways in Ventilated ALS Patients in Portugal and in Norway

Status unknown NA Last updated 2 March 2021
What this trial tests

NA trial testing Transnasal Fiberoptic Laryngoscopy in Amyotrophic Lateral Sclerosis in 60 participants. Status unknown.

Timeline
21 March 2019
Primary endpoint
31 December 2021
31 December 2022

Quick facts

Lead sponsorTiina Maarit Andersen
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment60
Start date21 March 2019
Primary completion31 December 2021
Estimated completion31 December 2022
Sites2 locations across Portugal, Norway

Drugs / interventions tested

Conditions studied

Sponsor

Tiina Maarit Andersen

Who can join

18 and older, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study examines if titration of Non-Invasive mechanical ventilation (NIV) settings during ongoing laryngoscopic visualization can improve the compliance of NIV in subjects with Amyotrophic Lateral Sclerosis (ALS). The study is a multicentre study between Norwegian National Advisory Unit on Long-term Mechanical Ventilation at the Thoracic Department, Haukeland University Hospital, Bergen, Norway and Centro Hospital Tras-os-Montes e Alto Douro, Vila Real, Portugal.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transnasal Fiberoptic Laryngoscopy

Trials testing the same drug.

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03887338.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing